PureTech Announces Completion of Enrollment in Phase 2b ELEVATE IPF Trial of LYT-100 (Deupirfenidone) in Idiopathic Pulmonary Fibrosis
PureTech Presents Data from LYT-100 (Deupirfenidone) Trial in Healthy Older Adults at CHEST Annual Meeting
PureTech announced a poster presentation describing the rationale and design for the Phase 2 trial of LYT-100 in patients with IPF at the European Respiratory Society (ERS) International Congress. The poster also reviews the results from a Phase 1 crossover trial of LYT-100 in healthy older adults, which supports the dose selection for the Phase 2 trial. (Graphic: Business Wire)